Trial Profile
A multi-center randomized, placebo-controlled, double-blind, parallel group, phase IIb proof of concept study with 3 oral groups of AZD3480 during 12 weeks treatment of cognitive deficits in patients with schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2012
Price :
$35
*
At a glance
- Drugs Ispronicline (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms HALO
- 01 Jan 2012 Results published in the Schizophrenia Research.
- 01 Jan 2012 Primary endpoint 'Assessment-scale-scores' has not been met.
- 01 Jan 2012 Primary endpoint 'Cognitive-function-tests' has not been met.